Corporate Profile

Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease.

The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives.

The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital... More >>

Recent News

More >>
FDA Approves Cardiovascular Systems’ Replacement Saline Infusion Pump 05/04/17
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) today announced that the U.S. Food and Drug Administration ( FDA ) has approved its premarket approval application (PMA) supplement for a redesigned saline pump used as part of the company’s Diamondback 360 ® Orbital Atherectomy Systems (OAS). The 70057-03 Saline Infusion Pump will replace CSI’s 7-10014 Saline Infusion Pump, which the company voluntarily recalled on April 17, 2017 . The company anticipates replacing all recalled units by no later than August 31, 2017. About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. , based in St. Paul, Minn. , is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Orbital Atherectomy Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter...
More >>
Cardiovascular Systems, Inc. Reports Fiscal 2017 Third-Quarter Financial Results 05/03/17
Cardiovascular Systems, Inc. (NASDAQ: CSII): Conference Call Scheduled for Today, May 3, 2017, at 3:45 PM CT (4:45 PM ET) Revenues of $52.1 million grew 17% compared to third quarter last year Net loss was $(1.7) million, or $(0.05) per share Includes $1.5 million charge related to voluntary recall of Saline Infusion Pumps and $1.3 million charge related to employee lawsuit Cash position grew $23.9 million to $103.1 million Diamondback 360 ® Coronary Orbital Atherectomy System (OAS) Micro Crown approved in Japan and US First subject enrolled in ECLIPSE coronary clinical trial Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for peripheral and coronary artery disease, today reported financial results for its fiscal third quarter ended March 31, 2017 . The company’s third-quarter revenues were $52.1 million, a 17% increase from the third quarter of fiscal 2016. Coronary revenues grew...
More >>

Upcoming Events

No items found